02:05:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 Ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2021-10-22 08:30:00
  • As part of their established collaboration agreement, IRRAS, Aarhus University, and Aarhus University Hospital will collectively work to quantify brain compliance using the company's IRRAflow system.
  • The combination of compliance calculations and IRRAflow treatment may provide real-time data that determines effectiveness and completion of therapeutic treatment.

Stockholm, October 22, 2021 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial project from its previously announced collaboration with Aarhus University Hospital in Aarhus, Denmark, one of the world's leading medical institutions. In conjunction with the Aarhus University's Technology Transfer Office (TTO) and Department of Electrical and Computer Engineering (ECE), and neurosurgeon Dr. Anders Korshøj, IRRAS will work to develop brain compliance monitoring software that resides on its flagship product, IRRAflow. When combined with IRRAflow's active treatment, such software would improve decision-making by providing physicians real-time information regarding the effectiveness and completion of treatment.

"Our mission at IRRAS is to develop innovative technologies that fundamentally change how neurocritical care patients are treated, and being able to measure brain compliance in real-time is a perfect example," said Will Martin, President and CEO of IRRAS.  "Partnering with leading experts in this field to advance their patient treatment with IRRAflow and collaboratively develop groundbreaking technology is critical to our long-term success."

Intracranial compliance expresses the capability of a patient's brain to withstand an increase in intracranial volume without experiencing a corresponding rise in intracranial pressure (ICP). Measuring intracranial compliance can provide physicians a real-time predictive and quantitative value that helps determine the extent of damage to the brain and how well the patient is responding to therapy. 

Dr. Anders Korshøj, Associate Professor of Neurosurgery at Aarhus University Hospital, will lead the collaboration together with Naveed Ur Rehman, Assistant Professor in the Department of Electrical and Computer Engineering at Aarhus University, utilizing specialists from IRRAS, the hospital's neurocritical care team, and data analytics experts from the Signal Processing and Machine Learning group at Aarhus University. 

"We are truly excited to engage in this multidisciplinary collaboration between IRRAS and our academic institutions," said Dr. Korshøj. "At Aarhus University Hospital, we set the highest standards to bring innovative treatments like IRRAflow to patients and aim to advance treatments to the next level. This project is a strong example of our dedicated collective focus and close collaboration with leading experts in medical engineering to realize our ambition."

Signal processing experts from the Department of Electrical and Computer Engineering at Aarhus University will play a key role in developing this novel technique to estimate brain compliance in real-time. Assistant Professor, Naveed ur Rehman, who heads the nonstationary signal processing group at ECE, will lead this specific activity.

"Our active participation in this interdisciplinary project is in line with our department's mission to not only create new knowledge but to also shape these creations into workable solutions that better society," said ur Rehman. "We strongly believe that this collaborative project will result in new ways to better treat neurotrauma patients, which is a goal that excites and motivates us as engineers."

The Technology Transfer Office is a division of Aarhus University that provides resources and partnership opportunities to achieve commercialization of research projects. As part of this collaborative project, IRRAS shall retain an exclusive option to license the resulting technology. Eoin Galligan, Senior Business Development Manager, worked with Dr. Korshøj on the negotiations with IRRAS.

"TTO Business Development is very happy to complete this process and support this partnership with IRRAS," said Galligan. "This project highlights how innovation partnerships can create `research impact,' access corporate sponsorship for research, and bring next-generation technology into the clinic."

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS). 

About Aarhus University and Aarhus University Hospital

Aarhus University Hospital belongs to the elite of university hospitals. Aarhus University Hospital develops and provides highly specialized medical treatment, research, and education at an international level. Aarhus University Hospital serves the citizens from across the central Denmark region in need of highly specialized treatment. For the last 14 years, Aarhus University Hospital has been appointed Denmark's best hospital, and it currently ranks #32 on the Newsweek ranking of the world's best hospitals.

Aarhus University (AU) is a dynamic, modern and highly international university. Since its founding in 1928, it has grown to become a leading public university with international impact and reach across the entire research spectrum. Out of over 17,000 universities worldwide, AU ranks among the top 100 universities in the world in several research areas and is considered among the top 25 universities in the European Union. AU stands out in particular in terms of research quality and the quality of degree programs. Regarding internationalization, AU is ranked in the top as well as no. 45 on THE's ranking "Most International Universities in the World".

The Department of Electrical and Computer Engineering at Aarhus University focus on research into hardware and software technologies that play a vital role in defining modern society, its digitalization and human behavior therein.

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com

Europe
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on October 22, 2021 at 08:30 (CET).